Bullous pemphigoid is an acquired autoimmune disease that causes blistering of the skin and mucosal membranes. The disease commonly affects people aged 60 years and above and is characterized by the presence of large, thick-walled blisters on the skin. Bullous pemphigoid blisters are fluid-filled and usually occur in clusters and are generally not painful. However, they can rupture easily leading to open sores. The exact causes for bullous pemphigoid are unknown but it is believed to occur due to the immune system attacking skin proteins. Diagnosis involves examination of skin for blisters and testing skin samples. Treatment depends on the severity of symptoms and primarily involves use of corticosteroids and immunosuppressant drugs that target the immune system.
The Bullous Pemphigoid Market is estimated to be valued at US$ 1.4 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the Bullous Pemphigoid Market are GlaxoSmithKline, Novartis, Pfizer, AstraZeneca, and Roche. These companies collectively account for over 50% of the global market share due to their strong product portfolios and global distribution networks. GlaxoSmithKline's SINGULAIR is the top selling drug in the bullous pemphigoid therapeutics segment.
Some of the key opportunities in the bullous pemphigoid market include development of novel targeted therapies and oral treatments. Traditionally treatment has focused on lifelong use of systemic corticosteroids which have several adverse effects. There is an unmet need for safer and more targeted treatment options. Rising prevalence of the disease also presents an opportunity for manufacturers to expand their product offerings.
The bullous pemphigoid market is also witnessing increased global expansion activities by prominent market players. For instance, in 2021 Roche announced plans to set up a new manufacturing plant in India to boost production of its autoimmune disease drugs including pemphigus and pemphigoid treatments. Other manufacturers are also focusing on emerging Asian and Latin American countries through local partnerships to meet the needs of underserved populations.
Market Drivers
One of the key drivers for the bullous pemphigoid market is the increasing geriatric population worldwide who are at a higher risk of developing the condition. According to WHO, the percentage of the global population aged 60 years and above is expected to nearly double from 12% to 22% between 2015 and 2050. This rising trend presents an opportunity for drugs and therapies targeting age-related skin diseases like bullous pemphigoid.
Market Restraints
However, the growth of the bullous pemphigoid therapeutics market is limited by certain factors. Firstly, low awareness globally regarding bullous pemphigoid symptoms and available treatment options poses a major barrier. Since its incidence is higher in elderly, some cases may remain undiagnosed. Secondly, high cost of advanced biologic treatments also restricts their widespread adoption, especially in price-sensitive developing regions. This necessitates development of lower-cost generics and biosimilars.
Segment Analysis
The Bullous Pemphigoid Market is segmented by therapy, distribution channel, and geography. By therapy, the corticosteroids segment held the largest market share in 2024 owing to effectiveness in reducing itching and inflammation. Corticosteroids are the first line treatment and help halt the disease progression by reducing immune response. Based on distribution channel, the hospital pharmacies segment dominated as most bullous pemphigoid patients require hospitalization for management of severe blisters and lesions.
Global Analysis
Regionally, North America captured over 40% of Bullous Pemphigoid Market in 2024 and is anticipated to grow at a high CAGR during the forecast period. This can be attributed to rising bullous pemphigoid prevalence, strong healthcare infrastructure, and availability of advanced treatment options in the region. Europe was the second largest market led by countries like Germany, UK, and France. However, Asia Pacific is likely to offer lucrative opportunities owing to geriatric population expansion and improving access to diagnosis and care in countries like China, India. Key players are focusing on emerging markets for long-term sustenance.
Get more insights on this topic: https://www.dailyprbulletin.com/bullous-pemphigoid-market-is-poised-to-witness-a-high-growth-driven-by-increasing-awareness-about-early-diagnostics/
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
What Are The Key Data Covered In This Bullous Pemphigoid Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Bullous Pemphigoid Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Bullous Pemphigoid Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Bullous Pemphigoid Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Bullous Pemphigoid Market vendors
FAQ’s
Q.1 What are the main factors influencing the Bullous Pemphigoid Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Bullous Pemphigoid Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Bullous Pemphigoid Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it